|
|
|
Issue Open Date
|
21-Nov-25
|
|
|
|
Issue Closing Date
|
25-Nov-25
|
|
|
|
Application Money
|
100
|
|
|
|
Allotment Money
|
|
|
|
|
|
|
|
Price Band
|
563
-
593
|
|
|
|
Minimium Application No.
|
25
|
|
|
|
Issue Size (Shares)
|
10564926
|
|
|
|
Market Lot
|
1
|
|
|
|
|
|
Objective
|
|
(i)Capital expenditure towards procurement of machinery for our production line located at Nandesari Facility I; and(ii)General corporate purposes.
|
|
|
|
|
|
|
Category
|
No. of Shares
|
No. of Shares
|
Subscription Ratio
|
|
|
Offered / Reserved |
Bid For |
|
|
Non-Institutional Investors
|
|
|
|
|
Qualified Institutional Buyers
|
|
|
|
|
Retail Individual Investors
|
|
|
|
|
|
|
|
Business Description
We are a technology led manufacturer of excipients and specialty ingredients for the pharmaceutical, food and nutrition industries and are dedicated to contributing to the global healthcare ecosystem. We leverage our inhouse developed technologies for processes such as encapsulation, spray drying, granulation, trituration, liposomal preparations and blending in an effort to drive innovation in our operations. We have established a presence in both, domestic and international markets, including key regions such as the United States, South America, Europe, the Middle East, Africa, and Asia-Pacific.We are one of the largest producers of food-grade iron phosphate for infant nutrition, clinical nutrition, and the food and beverage sectors, in terms of production capacity with a combined annual manufacturing capacity of 65,579 metric tons (“MT”), as of December 31, 2024. (Source: F&S Report) As of the same date, one of our Manufacturing Facilities has been approved by the United States Food and Drug Administration (“USFDA”) for the manufacture of mineral-based ingredients. We are one of the largest exporters of mineral ingredients for pharmaceutical, food and nutrition industries from India to global markets in terms of volume of products exported during 2024 as of December 31, 2024. (Source: F&S Report) We were the only company in India and one of nine companies globally with certification of suitability issued by the Council of Europe (“CEP”) and written confirmation certification for sale of calcium carbonate as an active pharmaceutical ingredient (“API”) in the European Union as of December 31, 2024. (Source: F&S Report) We are one of the pioneers in India to introduce a product range of liposomal ingredients for nutrient absorption and stability.
|
|
|
Promoter's Holding
|
|
|
|
Total Share Capital
|
99503523
|
|
|
|
Offered to Public
|
15092750
|
|
|
|
Promoter's Holding (Pre-Issue)
|
89.37
|
|
|
|
Promoter's Holding (Post-Issue)
|
|
|
|
|
|
|
|
|
|
|
|
Address |
129/1/ A
G. I. D. C. Estate
Nandesari
Vadodara,
Gujarat,
391340
Phone : 0265 284 0656/329 1354
Email : cs.sudeep@sudeepgroup.com
Website : https://www.sudeeppharma.com
|
|
|
Registrar |
MUFG Intime India Pvt Ltd.
C 101
247 Park
LBS Marg
Vikhroli (West)
Mumbai
|
|
|
Listed at |
|
BSE, NSE
|
|
|
Lead Manager |
ICICI Securities Ltd
IIFL Capital Services Ltd.
|
|
|
Promoters |
Avani Sujit Bhayani
Bhayani Family Trust
Riva Resources Pvt Ltd.
Shanil Sujit Bhayani
Sujeet Jaysukh Bhayani HUF
Sujit Jaysukh Bhayani
|
|
